State demonstration grants for comprehensive opioid abuse data

Title III of the Public Health Service Act (42 U.S.C. 241 et seq.) is amended by inserting after section 317U of such Act (42 U.S.C. 247b–23) the following:

317V.

State demonstration grants for comprehensive opioid abuse data

(a)

In general

The Secretary, in conjunction with the Director of the Centers for Disease Control and Prevention, may award grants to eligible entities—(1)to conduct research and develop a strategic response plan with respect to the opioid crisis; and(2)to establish and implement a co-prescribing program.(b)

Amount of grants

(1)

In general

The Secretary shall determine the amount of each grant awarded under this section on an annual basis. In allocating such amounts across grantees for a fiscal year, the Secretary shall award—(A)a minimum amount to each grantee in accordance with paragraph (2); and(B)an additional amount to each grantee in accordance with paragraph (3).(2)

Minimum amount

The Secretary shall—(A)determine the basis for determining the minimum amount of a grant under paragraph (1)(A); and(B)apply such basis consistently across all grantees under this section.(3)

Additional amount

In allocating additional amounts across all grantees under this section for a fiscal year, the Secretary shall give priority in setting such amounts to grantees with the highest opioid dispensing rates as determined by the Centers for Disease Control and Prevention.(c)

Priority in selection

In selecting grantees under this section, the Secretary shall give priority to eligible entities with the highest opioid dispensing rates as determined by the Centers for Disease Control and Prevention.(d)

Allocation of funds by a grantee

A grantee under this section shall allocate the funds received through the grant as follows:(1)Not more than 80 percent of the funds received through the grant shall be used to conduct research and develop a strategic plan in accordance with subsection (e).(2)At least 20 percent of the grant shall be used by the grantee to administer a co-prescribing program in accordance with subsection (f).(e)

Research; strategic plan

(1)

In general

Subject to subsection (d), a grantee under this section shall use the grant funds—(A)to conduct research on the impacts of the opioid crisis within the jurisdiction of the grantee; and(B)to develop a strategic plan to respond to the opioid crisis within such jurisdiction.(2)

Strategic plan contents

A strategic plan required by paragraph (1)(B) shall include plans for—(A)increasing public awareness about the opioid crisis within the jurisdiction of the grantee;(B)full-spectrum prevention within such jurisdiction;(C)intervention within such jurisdiction;(D)treatment and recovery within such jurisdiction; and(E)coordinating with law enforcement within such jurisdiction.(f)

Co-Prescribing program

(1)

In general

Subject to subsection (d), a grantee under this section shall use funds received through the grant to carry out a co-prescribing program under which the grantee requires—(A)health care practitioners in the jurisdiction of the grantee who prescribe an opioid for any patient to also prescribe an opioid overdose reversal drug for such patient if—(i)the opioid dosage prescribed is equal to or in excess of 50 morphine milligram equivalents per day;(ii)the practitioner prescribes a benzodiazepine for the patient or knows or reasonably should know a benzodiazepine has been prescribed for the patient in the past;(iii)the practitioner prescribes medication-assisted treatment for the patient or knows or reasonably should know medication assisted treatment has been prescribed for the patient in the past; or(iv)the practitioner knows or reasonably should know the patient has a history of substance use disorder;(B)such health care practitioners to complete continuing education on opioid prescribing; and(C)coroners in the jurisdiction of the grantee to complete continuing education on recognizing fatalities attributable to an opioid overdose.(2)

Waiver

If the laws, regulations, or orders of an applicant for a grant under this section conflict in any respect with the requirements of subparagraph (A), (B), or (C) of paragraph (1), the Secretary shall waive such requirements to the extent necessary to allow the grantee to carry out a co-prescribing program under this section. (g)

Supplement, not supplant

Grant funds under this section shall be used to supplement, not supplant, funding from other sources for the activities funded through the grant.(h)

Application

To seek a grant under this section, an eligible entity shall submit an application at such time, in such manner, and containing such information and assurances as the Secretary may require.(i)

Reporting

Not later than the end of each of fiscal years 2024 and 2026, a grantee under this section shall submit to the Secretary, the Director of the Centers for Disease Control and Prevention, and the appropriate congressional committees, and make publicly available, a report on the activities funded through the grant for each fiscal year covered by the report, including—(1)the allocation of funds for activities under subsection (e) versus activities under subsection (f);(2)a description of the research conducted by the grantee under subsection (e)(1)(A), including the results of such research;(3)an up-to-date version of the strategic plan developed under subsection (e)(1)(B); and(4)a description of the co-prescribing program under subsection (f), including an analysis of the effectiveness of the program.(j)

Definitions

In this section:(1)

Appropriate congressional committees

The term appropriate congressional committees means the Committee on Energy and Commerce of the House of Representatives and the Committee on Housing, Education, Labor, and Pensions of the Senate.(2)

Eligible entity

The term eligible entity means any State, any Indian Tribe, the District of Columbia, or any territory of the United States.(3)

Indian Tribe

The term Indian Tribe has the meaning given to such term in section 4 of the Indian Self-Determination and Education Assistance Act.(4)

Opioid overdose reversal drug

The term opioid overdose reversal drug means—(A)naloxone; or(B)any other emergency opioid antagonist approved by the Food and Drug Administration to treat an opioid overdose.(k)

Authorization of appropriations

To carry out this section, there are authorized to be appropriated such sums as may be necessary for each of fiscal years 2022 through 2026.